- The first participant has been dosed in a China-based Phase 3 clinical trial, PODIUM-304, evaluating Zai Lab Limited (NASDAQ:ZLAB) and Incyte's (NASDAQ:INCY) PD-1 inhibitor retifanlimab, combined with platinum-based chemo, in treatment-naïve patients with metastatic non-small cell lung cancer (NSCLC).
- The primary endpoints of the 530-subject study are overall survival and progression-free survival. The estimated primary completion date is August 2024.
- https://seekingalpha.com/news/3619737-zai-lab-commences-late-stage-study-of-retifanlimab-in-lung-cancer
Monday, October 5, 2020
Zai Lab commences late-stage study of retifanlimab in lung cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.